Novartis Q1 2026 Earnings Show Growth Beyond Patent Cliff

Kisqali, Pluvicto, and Kesimpta posted combined growth above 50 percent, signalling that Novartis’s post-patent transition is advancing faster than headline numbers suggest.

Key Takeaways

• Net sales of $13.1 billion fell 5 percent at constant currencies as generic erosion from Entresto offset 13 percentage points of volume growth driven by priority brands.
• Kisqali surged 55 percent to $1.5 billion, Pluvicto rose 70 percent to $642 million, and Scemblix jumped 79 percent, confirming the commercial credibility of the next-generation portfolio.
• Full-year guidance was reaffirmed, with low single-digit sales growth expected at constant currencies as the priority brand acceleration increasingly offsets the generics overhang.

A Transition Hiding in Plain Sight

First-quarter results from Novartis, released on April 28, presented a familiar paradox for pharmaceutical investors: headline numbers softened by structural forces that were, by design, already absorbed into market expectations. Net sales of $13.113 billion represented a 1 percent decline in reported dollars and 5 percent at constant currencies. Core operating income fell to $4.897 billion, compressing the core margin to 37.3 percent. On the surface, a difficult quarter. Beneath it, a more instructive one.

The arithmetic is worth unpacking. Volume growth contributed 13 percentage points to the top line, a figure that, in almost any other context, would define a strong quarter outright. That momentum was neutralised by 14 points of generic erosion and a further 4-point pricing drag, with U.S. revenue deduction adjustments amplifying the effect. Currency provided a modest offset. The result is a company running two parallel businesses simultaneously: a legacy portfolio under severe competitive pressure and an ascending franchise that is, by every commercial measure, the actual point of the enterprise.

The Brands That Define the Next Decade

The priority portfolio is performing with a consistency that matters to long-term investors. Kisqali, the CDK4/6 inhibitor for breast cancer, delivered $1.516 billion in the quarter, up 55 percent at constant currencies, cementing its position across both early-stage and metastatic settings. That breadth of label coverage differentiates it from narrower oncology assets and insulates revenue against competition in any single indication. At current trajectories, annual revenues approaching $6 billion are a credible medium-term prospect. Pluvicto, the radioligand therapy for metastatic castration-resistant prostate cancer, advanced 70 percent to $642 million, its expansion into pre-taxane settings opening a materially broader patient population.

Kesimpta reached $1.164 billion, up 26 percent, reinforcing its standing in multiple sclerosis. Leqvio climbed 69 percent to $452 million, with China contributing meaningfully to incremental gains. Scemblix rose 79 percent to $433 million in chronic myeloid leukaemia. Taken together, five assets growing at rates between 26 and 79 percent, each with long remaining patent lives, strong clinical differentiation, and pricing power sustained by genuine unmet need, constitute a commercially coherent portfolio whose combined scale will, within a manageable horizon, redefine what Novartis looks like financially.

The Weight of Entresto and the Logic of the Cliff

The other side of the ledger is equally instructive. Entresto posted $1.305 billion in the quarter, a 46 percent decline at constant currencies following U.S. loss of exclusivity in mid-2025. The scale of that erosion illustrates a dynamic every major pharmaceutical investor understands: a single franchise generating several billion dollars annually can, within a few quarters of generic entry, contract to a fraction of its former footprint. Cosentyx, after revenue deduction adjustments, was essentially flat at $1.566 billion. The established brands portfolio declined sharply across the board.

The relevant question is not whether Novartis faces a demanding transition, which it plainly does, but whether the incoming portfolio is growing fast enough to absorb the losses and then surpass them. Full-year 2026 guidance, reaffirmed without revision, projects low single-digit constant-currency sales growth and a low single-digit decline in core operating income. That framework assumes continued Entresto erosion offset by accelerating brand performance, a balance the Q1 numbers suggest is tracking broadly as modelled. The crossover point, where growth brands fully displace the legacy drag, is increasingly a question of timing rather than probability.

Avidity, the RNA Platform, and Strategic Discipline

The quarter’s most consequential development was the completion of the Avidity Biosciences acquisition. The deal, at approximately $12 billion, brings three late-stage neuromuscular assets alongside proprietary oligonucleotide delivery technology that materially advances Novartis’s capacity in RNA-based therapeutics. The xRNA platform is an area of articulated medium-term ambition, and Avidity provides both clinical pipeline depth and delivery expertise that would have taken considerably longer to develop organically. Pipeline momentum elsewhere was constructive: Phase III data for remibrutinib in chronic inducible urticaria, Phase II results in food allergy, FDA priority review for Fabhalta in IgA nephropathy, and paediatric approvals for Cosentyx in hidradenitis suppurativa collectively extend the company’s near-term regulatory horizon across immunology, renal, and dermatology.

Novartis’s approach to capital deployment has been deliberately measured since the Sandoz spin-off in 2023. Avidity follows the same logic as earlier bolt-on deals: specific scientific capability, a defined platform fit, and no balance-sheet overextension. Net debt rose to $38.1 billion, but free cash flow held at $3.330 billion and the company repurchased 10.4 million shares for $1.6 billion in the quarter. That combination of acquisition, buyback, and dividend execution within a single quarter signals a management team operating with genuine financial confidence rather than optionality.

What the Market Already Knows

Novartis AG (NASDAQ: NVS) shares closed the session down approximately 0.9 percent at $144.19, a reaction so contained it amounts to market endorsement of the narrative. Consensus revenue estimates had hovered near $13.5 billion, and the miss was attributed entirely to the anticipated Entresto dynamic rather than any deterioration in the underlying business. The muted response reflects a market that has already priced the near-term generics cycle and is holding its position in anticipation of the portfolio inflection that the priority brand data increasingly support.

The medium-term ambition of 5 to 6 percent constant-currency revenue growth and a core margin approaching the mid-40 percent range by decade’s end is no longer a strategic aspiration resting on projections. It is now being tested, quarter by quarter, against a live commercial portfolio. On the evidence of Q1 2026, that test is proceeding as expected, which in a sector defined by uncertainty and long lead times, is precisely the signal that institutional investors are looking for.